genetically engineered macrophages co-expressing IL-10 and dominant-negative TGFbetaR2 (Carisma Therapeutics)

N/A

Report date: 2025/06/11 11:07:20

Base Information

Drug Namegenetically engineered macrophages co-expressing IL-10 and dominant-negative TGFbetaR2 (Carisma Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy
Mechanisms of ActionMacrophages stimulantsInterleukin 10 receptor agonistsTransforming growth factor beta inhibitors
TargetsTransforming growth factor betaInterleukin 10 receptor
Therapy Area/IndicationsPulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCarisma Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCarisma Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A